Clinical trials: Osler-Rendu Disease
Osler Rendu Disease, Hereditary Hemorrhagic Telangiectasia
Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT)
Hereditary Haemorrhagic Telangiectasia (HHT) is a rare inherited genetic disease of autosomal dominant inheritance with a prevalence of about 1/5000.
- Trial name
- CONCERTO (NCT03691142)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 207 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds
Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied will diminish epistaxis in patients with HHT…
- Trial name
- NCT01406639
- Testing
- Ranibizumab
- Sponsor
- University of California, San Diego
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed
- Trial name
- Paz (NCT03850964)
- Testing
- Pazopanib
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Topical TOR-582 Treatment of Epistaxis in HHT
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life.
- Trial name
- NCT07667413
- Testing
- Topical sirolimus ointment
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
Hereditary Hemorrhagic Telangiectasia
Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients
OBJECTIVES: I. Collect data regarding the natural history of hereditary hemorrhagic telangiectasia (HHT). II. Establish genotype-phenotype correlations in HHT. III.
- Trial name
- NCT00004649
- Sponsor
- National Center for Research Resources (NCRR)
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Pulmonary Arteriovenous Malformations
Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy
AVMs are abnormal collections of blood vessels which can occur in any part of the body including the lungs. These blood vessels are weakened and can rupture anytime causing bleeding which can be massive, leading to…
- Trial name
- NCT01856842
- Testing
- Angiography and embolotherapy
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Unity Health Toronto
Telangiectasia, Hereditary Hemorrhagic
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs).
- Trial name
- NCT00230672
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
This study will investigate the effectiveness of oral low-dose tacrolimus for the treatment of recurrent nasal hemorrhage in HHT subjects.
- Trial name
- NCT04646356
- Testing
- Tacrolimus capsule (low-dose)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Telangiectasia, Hereditary Hemorrhagic
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Patients affected by hereditary hemorrhagic telangiectasia (HHT) very often suffer from recurrent nosebleeds called epistaxis. There is no treatment currently available to reduce the frequency or severity of epistaxis.
- Trial name
- EPISTOP (NCT04976036)
- Testing
- Nintedanib
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people
- Sponsor
- Dr. Romain Lazor
Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
The purpose of this study is to determine whether long-acting octreotide is safe and effective in the treatment of patients with Rendu-Osler-Weber (e.g. HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia
- Trial name
- ROW (NCT02874326)
- Testing
- Octreotide LAR
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Telangiectasia, Hereditary Hemorrhagic
Pomalidomide for the Treatment of Bleeding in HHT
This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or…
- Trial name
- PATH-HHT (NCT03910244)
- Testing
- Pomalidomide Oral Product
- Where
- 14 sites in United States
- Volunteers
- 145 people
- Sponsor
- The Cleveland Clinic
Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment.
- Trial name
- EPERO (NCT04113187)
- Testing
- Propranolol treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Bordeaux
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
Stress-Echography in Hereditary Haemorrhagic Telangiectasia Patient With Hepatic Involvement
The hepatic involvement of HHT (Hereditary Haemorrhagic Telangiectasia) disease is characterised by the formation of arterio-sus-hepatic shunts which lead to dilatation of the hepatic artery and may result in high output heart…
- Trial name
- ROSE (NCT05954481)
- Testing
- Stress echocardiography
- Where
- 2 sites in France
- Volunteers
- 47 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia
MRA With Feraheme in HHT
Magnetic resonance (MR) imaging is performed with contrast agents to highlight the blood vessels and allow interpretation and diagnosis of blood vessel abnormalities.
- Trial name
- NCT02977637
- Testing
- Feraheme MRI/MRA
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Los Angeles
Hereditary Hemorrhagic Telangiectasia (HHT)
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT.
- Trial name
- PATH-HHT ATLAS (NCT07018401)
- Testing
- Pomalidomide
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
HHT, Morbus Osler
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
In a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in patients suffering from Hereditary Haemorrhagic Telangiectasia together with KTP Laser therapy.
- Conditions
- HHT, Morbus Osler, Epistaxis
- Trial name
- NCT01314274
- Testing
- Bevacizumab, NaCl
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University of Vienna
Hereditary Hemorrhagic Telangiectasia (HHT)
Graded TTCE for Post-Embolization PAVM Monitoring
Current HHT guidelines recommend CT scan to detect new or recurrent PAVMs after embolotherapy. Recent studies using transthoracic contrast echocardiography (TTCE) shunt grade for PAVM screening suggest that graded TTCE can…
- Trial name
- NCT02936349
- Testing
- Transthoracic Contrast Echocardiogram
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
Hereditary Hemorrhagic Telangiectasia (HHT)
Doxycycline for Hereditary Hemorrhagic Telangiectasia
This study will investigate the effectiveness of oral doxycycline for the treatment of recurrent nasal hemorrhage in Hereditary Hemorrhagic Telangiectasia (HHT) subjects.
- Trial name
- HHT (NCT03397004)
- Testing
- Doxycycline Hyclate
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Unity Health Toronto
Hereditary Haemorrhagic Telangiectasia
Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome patients are carriers of a heterozygous mutation of the activin receptor-like kinase 1 (ACVRL1), Endoglin (ENG) or Mothers against decapentaplegic homolog…
- Trial name
- CAERO (NCT05632484)
- Testing
- Cord blood sampling, Cord sampling
- Where
- 3 sites in France
- Volunteers
- 16 people
- Sponsor
- Hospices Civils de Lyon